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Background  
 
Thyroid nodules are defined as discrete lesions within the thyroid gland, radiologically 
distinct from surrounding thyroid parenchyma. Their diagnosis is increasingly frequent in clinical 
practice (Durante, et al. 2018). 
With neck palpation, thyroid nodule prevalence in iodine sufficient populations has been 
estimated to about 5%, depending on age and sex (Mazzaferri 1993). Nowadays, however, 
clinicians are asked to manage a much higher rate of asymptomatic patients with “occult” thyroid 
nodules (up to 68% of the general population) (Guth, et al. 2009). This is largely due to the 
incidental discovery of asymptomatic nodules, mainly during diagnostic imaging test for other 
purposes (so-called “thyroid incidentalomas”). The prevalence is reported about 15% with 
computed tomography (CT) or magnetic resonance imaging (MRI), and 1-2% with 18-
fluorodeoxyglucose (FDG) positron emission tomography (PET) (Russ, et al. 2014). The risk of 
malignancy in case of ultrasound (US), CT or MRI incidentalomas ranges between 5 and 13%, 
while in case of focal FDG uptake, the expected malignancy rate may increase up to 55% (Russ et 
al. 2014; Sharma, et al. 2015). Recognized risk factors for malignancy are head and neck and whole 
body irradiation (Aldrink, et al. 2016; Cahoon, et al. 2017), exposure to ionizing radiation from 
fallout in young age (Land, et al. 2015), hereditary syndromes that include thyroid cancer (e.g., 
multiple endocrine neoplasia syndrome type 2, familial adenomatous polyposis). Clinical features 
such as rapid nodule growth and hoarseness also increase the probability of malignancy (Haugen, et 
al. 2016).  
The main clinical goal is the detection of the clinically relevant nodules (mainly those 
harboring a clinically significant malignancy) among their sizable number in the general population: 
in fact, the majority of nodules are benign, and so remain during long-term follow-up. Currently 
used diagnostic tools are: ultrasonography, cytology, and molecular testing. 
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Thyroid ultrasonography 
 
Thyroid sonography is the main tool used for initial cancer risk stratification of thyroid 
nodules. It is the preferred imaging modality: high frequency linear matrix probes (12 mHz) provide 
excellent image resolution, because the thyroid is a superficial gland, with its posterior border 
generally situated at less than 4 cm depth from the cutaneous surface. For this reason, if a thyroid 
nodule is incidentally detected on another radiologic study, a sonographic re-evaluation is suggested 
(Durante et al. 2018; Haugen et al. 2016). A complete diagnostic ultrasound examination should 
include description of the background thyroid parenchyma, nodule location and size (in 3 
dimensions), and a survey of the cervical lymph nodes (AIUM 2013). Individual sonographic 
features may help stratifying the risk of malignancy of thyroid nodules, because some of them are 
associated with thyroid cancer (e.g. solid composition, hypoechogenicity, irregular margins, and 
microcalcifications) while others are more likely to indicate benignity (cystic content, “spongiform” 
appearance) (Brito, et al. 2014; Campanella, et al. 2014; Moon, et al. 2012). The cancer risk is also 
low (<5-10%) for solid noncalcified smoothly marginated nodules that are either iso- or 
hyperechoic (same or lighter greyscale imaging compared to normal thyroid) (Moon, et al. 2008). 
 
The American Thyroid Association (ATA) (Haugen et al. 2016) and multiple other 
professional groups (Gharib, et al. 2016; Russ, et al. 2017; Shin, et al. 2016; Tessler, et al. 2017) 
have devised similar, even if not identical systems, aiming to classify nodules by 
patterns/combinations of sonographic features, according to their cancer risk, and then to 
recommend graduated size cut-offs for fine-needle aspiration biopsy (FNAB) (Table 1). Guidelines 
from endocrinology societies have generally focused on nodule pattern identification (Gharib et al. 
2016; Haugen et al. 2016; Russ et al. 2017), accompanied by figures illustrating these patterns, with 
correlation of each pattern to an estimated cancer risk.  Recently, the American College of 
Radiology (ACR) (Tessler et al. 2017) has recommended a point scale for systematic assessment of 
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imaging for thyroid nodules (TIRADS, Thyroid Imaging Reporting and Data System), similar to the 
approach used by radiologists for other organs.  Points are assigned based upon 5 ultrasound 
features and the sum determines the TIRADS classification of the nodule, its estimated cancer risk, 
and recommendations for either FNAB or surveillance. Malignancy risk estimates based upon 
sonographic appearance is generally very similar among all 4 classification systems; however, there 
are some differences in FNAB recommended cutoff sizes. 
The sonographic features included in each classification system tiers are listed in Table 1.  
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Table 1. An overview of the standardized sonographic scoring systems proposed or endorsed by international practice guidelines for risk-
based guidance in planning FNAB of thyroid nodules. Modified from (Durante et al. 2018) 
 
AACE/ACE/AME 
(Gharib et al. 2016) 
ATA 
(Haugen et al. 2016) 
EU-TIRADS 
(Russ et al. 2017) 
ACR TIRADS 
(Tessler et al. 2017) 
K-TIRADS 
(Shin et al. 2016) 
Low-risk 
Risk of malignancy 1% 
FNAB >20 mm (selective)a 
 
Cysts (fluid component 
>80%). 
Mostly cystic nodules with 
reverberating artifacts and not 
associated with suspicious US 
signs.  
Isoechoic spongiform 
nodules, either confluent or 
with regular halo. 
 
 
Benign 
Risk of malignancy <1% 
FNAB is not indicated 
 
Purely cystic nodules (no 
solid component) 
 
 
 
 
Benign (EU-TIRADS 2) 
Risk of malignancy ≈ 0% 
FNAB is not indicated 
 
Pure, anechoic cysts; 
Entirely spongiform nodules 
 
 
 
  
TR1 Benign 
Risk of malignancy 2% 
FNAB is not indicated 
 
Spongiform 
Pure cyst 
 
TR2 Not suspicious 
Risk of malignancy 2% 
FNAB is not indicated 
 
Mixed cystic or solid 
noncalcified nodules with 
smooth margins and oval 
shape 
Benign 
ROM <1-3% 
FNAB≥20 mm 
 
Spongiform  
Partially cystic nodule with 
comet-tail artifact 
Pure cyst 
 
Very low suspicion 
Risk of malignancy <3% 
FNAB ≥20 mm or observation 
 
Spongiform or partially cystic 
nodules without any of the US 
features defining low-, 
intermediate- or high-
suspicion patterns 
Low-Risk (EU-TIRADS 3) 
Risk of malignancy 2-4% 
FNAB >20 mm 
 
Oval shape, smooth margins, 
isoechoic or hyperechoic, 
without any feature of high 
risk 
 
 
 
TR3 Mildly suspicious 
Risk of malignancy 3% 
FNAB >25mm 
 
Isoechoic solid or hypoechoic 
cystic noncalcified nodules 
with smooth margins and oval 
shape 
Low suspicion 
ROM 3-15% 
FNAB ≥ 15 mm 
 
Partially cystic or 
isohyperechoic 
nodule without any of 3 
suspicious 
US features 
 
 
Low suspicion 
Risk of malignancy 5-10% 
FNAB ≥15 mm 
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Isoechoic or hyperechoic solid 
nodule, or partially cystic 
nodule with eccentric solid 
area without: 
microcalcifications, irregular 
margin, extrathyroidal 
extension, taller than wide 
shape. 
Intermediate-risk 
Risk of malignancy 5-15% 
FNAB: >20mm 
 
Slightly hypoechoic (vs. 
thyroid tissue) or isoechoic 
nodules, with ovoid-to-round 
shape, smooth or ill-defined 
margins 
May be present: 
• Intranodular 
vascularization  
• Elevated stiffness at 
elastography,  
• Macro or continuous rim 
calcifications 
• Indeterminate 
hyperechoic spots 
Intermediate suspicion 
Risk of malignancy 10-20% 
FNAB ≥10 mm 
 
Hypoechoic solid nodule with 
smooth margins without: 
microcalcifications, 
extrathyroidal extension or 
taller than wide shape 
 
Intermediate-Risk (EU-
TIRADS 4) 
Risk of malignancy 6-17% 
FNAB >15 mm 
Oval shape, smooth margins, 
mildly hypoechoic, without 
any feature of high risk 
 
TR4 Moderately Suspicious 
Risk of malignancy 5-20% 
FNAB >15mm 
 
Hypoechoic solid noncalcified 
nodules with oval shape and 
either smooth or irregular or 
lobulated margins  
 
Isoechoic solid or mixed 
noncalcified nodules with 
either nonparallel orientation 
(taller than wide) or punctate 
echogenic foci 
 
Intermediate suspicion 
ROM 15–50% 
FNAB ≥10 mm 
Solid hypoechoic nodule 
without any suspicious US 
feature or partially cystic or 
isohyperechoic 
nodule with any of the 
following: microcalcification, 
nonparallel orientation (taller-
than-wide), 
spiculated/microlobulated 
margin 
 
High-risk 
Risk of malignancy 50-90% b 
FNAB ≥10 mm (5 mm, 
selective c) 
Nodules with ≥1 of the 
following: 
• Marked hypoechogenicity 
(vs. prethyroid muscles) 
High suspicion 
Risk of malignancy >70-90% 
FNAB ≥10 mm 
 
Solid hypoechoic nodule or 
solid hypoechoic component 
of partially cystic nodule with 
≥1 of the following: 
High-Risk (EU-TIRADS 5) 
Risk of malignancy 26-87% 
FNAB >10 mm 
 
Nodules with ≥1 of the following:  
• Non-oval shape 
• Irregular margins 
• Microcalcifications  
• Marked hypoechogenicity 
TR5 Suspicious 
Risk of malignancy “at least 
20%” 
FNAB >10mm 
 
Hypoechoic solid nodule with 
any of the following: 
• Nonparallel orientation 
(taller-than-wide) 
High suspicion 
ROM >60% 
FNAB ≥10 mm (>5 mm, 
selectived) 
Solid hypoechoic nodule with 
any of the following: 
• Microcalcification 
• Nonparallel orientation 
(taller-than-wide) 
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• Spiculated or lobulated 
margins  
• Microcalcifications 
• Taller-than-wide shape 
(AP>TR) 
• Extrathyroidal growth  
• Pathologic adenopathy 
• Irregular margins 
(infiltrative, 
microlobulated) 
• Microcalcifications 
• Taller than wide shape 
• Rim calcifications with 
small extrusive soft tissue  
• Extrathyroidal extension 
 • Extrathyroidal extension 
• Punctate echogenic foci 
 
Isoechoic solid nodule with 
irregular or lobulated margins 
and either peripheral rim 
calcifications or punctate 
echogenic foci 
 
 
• Spiculated/microlobulated 
margin 
 
 
 
Abbreviations. AACE/ACE/AME: American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione 
Medici Endocrinologi; ACR: American College of Radiologists; ATA: American Thyroid Association. EU-TIRADS: European Thyroid Imaging 
Reporting and Data System; FNAB: fine-needle aspiration; TR: American College of Radiologists Thyroid Imaging Reporting and Data System.  
FNAB indicates the size above which a fine-needle aspiration cytology is recommended. 
a Growing nodule, high-risk history, before surgery or local therapies. 
b In accordance with the presence of 1 or more suspicious findings. 
c FNAB is recommended for smaller nodules in the following cases: subcapsular or paratracheal lesions; suspicious lymph nodes or extrathyroid 
spread; personal or family history of thyroid cancer; history of head and neck irradiation; coexistent suspicious clinical findings (e.g., dysphonia). 
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Cytology 
 
Cytology usually provides the most definitive diagnostic information for the evaluation of 
thyroid nodules (Haugen et al. 2016). FNAB is simple, safe, and reliable, and is usually performed 
under ultrasound guidance. In the United States and much of the world, thyroid cytologic results 
reporting is stratified using the Bethesda classification system which provides six diagnostic 
categories (Table 2). An updated version of the Bethesda system was recently published including 
minor changes in the nomenclature and the revision of the estimated malignancy risk for each class 
(Baloch, et al. 2017; Pusztaszeri, et al. 2016). Category 1 is "nondiagnostic" or "insufficient", 
category 2 is “benign”, and categories 5 and 6 are “suspicious for malignancy” and "malignant", 
respectively.  Despite interobserver differences in cytologic interpretation (Cibas, et al. 2013), 
Bethesda categories 2, 5, and 6 provide high enough predictive values for definite clinical decisions. 
However, categories 3, and 4, comprising about 20-30% of all biopsies, are "indeterminate" or 
“suspicious” readings, and usually require additional evaluation. In the U.S., the dominant strategy 
is the avoidance of surgery, because the majority of nodules in these three categories are benign 
(Bongiovanni, et al. 2012; Strickland, et al. 2015).  
The revised version of the Italian Consensus for Reporting Thyroid Cytopathology 
published in 2014 (Nardi, et al. 2014), is a six-tiered system almost comparable to the Bethesda 
system. The original TIR3 category was splitted in two subcategories: TIR3A, which comprises 
specimens with increased cellularity with follicular pattern, or oxyphilic cells, is similar to the 
Bethesda category 3, while TIR3B resembles Bethesda category 4 and includes lesions with high 
cellularity characterized by a repetitive microfollicular or trabecular pattern but also those with 
mild-focal nuclear alterations suggestive of papillary carcinoma.  
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Table 2. Bethesda System and Italian Consensus for Reporting Thyroid Cytopathology 
synopsis: estimated risk of malignancy and suggestions for clinical management.  
The Bethesda System for 
Reporting Thyroid  
Cytopathology (Cibas and Ali 
2017) 
Risk of 
malignancy 
(%) 
The Italian 
Consensus for 
Reporting Thyroid 
Cytopathology  
 
Usual management  
(other factors may influence 
management) 
Nondiagnostic or 
Unsatisfactory 
Cyst fluid only 
Virtually acellular 
specimen 
Obscuring blood, 
artifacts. 
0-5 
(risk of 
malignancy 
varies with the 
type/structure 
of the nodule) 
TIR 1 (Nondiagnostic) Repeat FNAB with ultrasound 
guidance 
Benign 
Benign follicular 
nodule (e.g., 
adenomatoid nodule, 
colloid nodule) 
Chronic lymphocytic 
(Hashimoto) thyroiditis 
Granulomatous 
(subacute) thyroiditis 
0–3a TIR 2 (benign) Clinical and sonographic 
follow-up  
Atypia of Undetermined 
Significance or  
Follicular Lesion of 
Undetermined Significance 
~10–30b TIR 3A (low-risk 
indeterminate lesion) 
[estimated risk <10%; 
published data 17%] 
Repeat FNAB, molecular 
testing, or lobectomy 
Follicular Neoplasm or  
Suspicious for a Follicular 
Neoplasmf  
Specify if oncocytic 
(Hürthle cell) type 
25-40c TIR 3B (high-risk 
indeterminate lesion) 
[estimated risk 15-
30%; published data 
47%] 
Molecular testing, lobectomy 
Suspicious for Malignancy 
Suspicious for papillary 
thyroid carcinoma 
50–75 TIR4 (suspicious for 
malignancy) 
Near-total thyroidectomy or 
lobectomy 
Some studies have 
recommended molecular 
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Suspicious for 
medullary thyroid 
carcinoma 
Suspicious for 
metastatic carcinoma 
Suspicious for 
lymphoma 
analysis to assess the type of 
surgical procedure 
(lobectomy vs. total 
thyroidectomy).  
Malignant 
Papillary thyroid 
carcinoma 
Poorly differentiated 
carcinoma 
Medullary thyroid 
carcinoma 
Undifferentiated 
(anaplastic) carcinoma 
Squamous cell 
carcinoma 
Carcinoma with mixed 
features  
97–99 TIR 5 (malignant) Near-total thyroidectomy 
(surgery may not be indicated 
in case of metastatic tumors; 
lobectomy is appropriate for 
papillary thyroid cancers < 4 
cm without other high-risk 
features) 
 
a) Estimate extrapolated from studies showing correlation between biopsied nodule and surgical 
pathology follow-up. 
 
b) Estimates extrapolated from histopathologic data from large case cohorts (including repeat 
atypical FNAs) and meta-analysis of the post 2007 literature  
 
c) Estimates extrapolated from histopathologic data from large case cohorts and meta-analysis of the 
post 2007 literature 
 
d) The measured malignancy rates for the Italian Consensus indeterminate cytology reports were 
derived by two recent systematic reviews and meta-analyses (Trimboli, et al. 2018a; Trimboli, et al. 
2018b)  
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Molecular testing 
 
Over the last years, our knowledge of the genetic mechanisms of thyroid cancer has 
expanded dramatically. A recent study from the Cancer Genome Atlas (Cancer Genome Atlas 
Research  Network 2014) provided comprehensive genetic characterization of papillary thyroid 
carcinoma (PTC), the most common type of thyroid cancer, identified two main classes of PTC, the 
“BRAF V600E-like” and “RAS-like,” each with its own biologic and clinical characteristics. The 
first class is characterized by classic papillary or tall-cell histology and reduced expression of 
differentiation markers such as thyroglobulin, thyroid peroxidase, and Na/I symporter; the second 
one is driven by RAS and similar mutations and gene fusions and characterized by follicular 
morphology and preserved expression of differentiation markers (Nikiforov 2017). Furthermore, 
novel genomic data were published about follicular thyroid cancer (Fagin and Wells 2016), Hürthle 
cell carcinoma (Ganly, et al. 2018), poorly differentiated, and anaplastic thyroid cancer (Landa, et 
al. 2016). Mutations occur principally in genes coding for proteins in the MAP kinase pathway that 
regulates cellular proliferation and differentiation. A mutation in the BRAF gene (V600E) is found 
in approximately 40% of PTC, as well as in some poorly differentiated and anaplastic cancers 
arising from PTC (Nikiforova, et al. 2003). Mutations in the RAS gene family are found in some 
PTC (usually follicular variant), follicular thyroid cancers, in benign follicular adenomas, as well as 
in NIFTP. The RET/PTC fusion gene, in which the RET gene is fused with the PTC gene is 
associated with radiation-related PTC, while another fusion gene (between the PAX8 and the PPARγ 
gene) is seen in some follicular thyroid cancers, in some follicular adenomas, and in follicular 
variant PTC.  Mutations in TERT and TP53 tumor suppressor genes have also been observed in 
some thyroid cancers and confer aggressive behavior. 
This knowledge provides the basis for clinical use of molecular markers in diagnosis and 
individualized management of patients with thyroid nodules. Molecular testing of FNAB specimens 
is now a popular (Burch, et al. 2016) and potentially practice changing approach (Duick, et al. 
13 
 
2012) to the issue of cytologically indeterminate nodules. The two most popular molecular testing 
strategies are “mutational analysis” and “gene expression analysis”, in which genetic information 
is can be derived from the same material obtained in the original FNAB sample.  Mutational 
analysis involves isolating DNA from thyroid follicular cells in the specimen and performing gene 
sequencing, focusing on possible mutations in relevant genes, as well for the presence of fusion 
genes (Nikiforov 2017). Mutational testing has been initially considered as “rule in test”, since if a 
known drive mutation is found, or if fusion genes are present, thyroid cancer is almost always 
present (Eszlinger, et al. 2017). However, mutations in RAS genes are seen in the full spectrum of 
thyroid pathology, from non-malignant thyroid neoplasms (adenomas) to invasive cancers and have 
less diagnostic utility.  Furthermore, if no mutations are found, a thyroid malignancy with a 
mutation that was not assessed could still be present, and therefore mutational testing may lead to 
both false negative and false positive results (the latter especially if RAS and RAS-like mutations 
are found). 
In a single institution study of 239 patients with Bethesda category 3 and 4 cytology, the mutational 
testing strategy (with an expanded number of genes tested; ThyroSeq v.2), yielded a negative 
predictive value (NPV) when a mutation was not found of about 96%, and a positive predictive 
value (PPV) of approximately 80%.(Nikiforov, et al. 2015) In a second single institution study of 
182 patients with 190 Bethesda category 3 and 4 cytologies, the NPV was 91% (82-97%) and the 
PPV was 42% (25-61%).(Valderrabano, et al. 2017) A new version of ThyroSeq (v.3), including 
additional mutations and fusions, was developed and assessed in a multicenter trial (Steward, et al. 
2018): it demonstrated a 94% (95% CI, 86%-98%) sensitivity and 82% (95% CI, 75%-87%) 
specificity in Bethesda III and IV nodules combined, with a NPV of 97% and a PPV of 66%. 
The second type of molecular testing, "gene expression analysis" or "gene expression 
classifier" (GEC) uses a proprietary algorithm (derived by machine learning protocols) to analyze 
the expression of specific genes in a 142-gene panel.  Nodules are classified as "benign" or 
"suspicious", and the test is designed to be a “rule out test” with high NPV. In a pooled analysis of 
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12 studies involving 1303 nodules, the NPV ranged from 87-96% (95% CI) with a malignancy 
prevalence rate varying from 29-34%.(Al-Qurayshi, et al. 2017) The GEC has a low positive 
predictive value, with a risk of malignancy in the range of 30-50% in the context of a "suspicious" 
GEC result. (Alexander, et al. 2012) The first version of this test is no longer available: a newer 
version (called Genomic Sequencing Classifier, including multiple new components), has a higher 
specificity (sensitivity of 91% and a specificity of 68%), resulting in a higher positive predictive 
value (PPV 47%), with a stable NPV of 96% (Patel, et al. 2018).  
 
MicroRNA (miRNA) analysis is a more recent methodology for molecular testing for which 
there are more limited data (Lithwick-Yanai, et al. 2017) but may prove to be useful in diagnostic 
decision making. Two commercial diagnostic tests use miRNAs: ThyGenX/ThyraMIR is a 
combination of a 7-gene mutation panel and a panel of 10 miRNA markers (ThyraMIR), with a 
combined NPV of 94% and PPV of 74%) (Labourier, et al. 2015), and Rosetta GX Reveal test, 
based on a panel of 24 miRNA, no more on the market. 
 
Molecular testing is expensive: about $3000-5000 per test in the United States, depending 
on the specific testing strategy (Nishino 2016); so, it is unaffordable in many parts of the world. 
Some studies suggest that molecular testing is cost-effective (Labourier 2016; Lee, et al. 2014; Yip, 
et al. 2012) since it decreases the number of diagnostic surgeries, and complications, when the test 
results are benign. However, the results vary depending on the test performance parameters, 
malignancy rates in the patient population, the health-care setting, among other factors (Eszlinger et 
al. 2017). 
 
  
15 
 
Table 3: Current commercially available molecular tests, with their main validation study 
 
ThyroSeq GC 
Steward, et al. 2018 
Afirma GEC 
Alexander et al. 2012 
Afirma GSC 
(Patel et al. 2018) 
Study Type Multicenter, 
prospective, double-
blind 
Multicenter, 
prospective, double-
blind 
Multicenter, 
retrospective, 
double-blind 
Nodules 257 210 191 
Cancer 
prevalence 
27.5 24.3 23.7 
Sensitivity 94.1 90.2 91.2 
Specificity 81.6 51.6 68.3 
NPV 97.3 94.3 96.1 
PPV 65.9 37.4 47.1 
Benign call 
rate 
61 41 54 
Avoidable 
surgeries  
82 52 68 
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Aims 
 
Multiple sonographic systems and molecular tests are now available to guide physicians in the 
management of thyroid nodules. Independent validation studies for sonographic systems were 
typically small and demonstrated inconsistencies between the results of different groups. Molecular 
tests are expensive, currently not commercially available in Italy, and the results of validation 
studies were usually not replicated in real clinical practice. 
 
The aims of the present project were to: 
1. Prospectively validate current sonographic classification systems for the risk evaluation of 
thyroid nodules; 
2. Propose a molecular test strategy for risk refinement in case of indeterminate cytology; 
3. Propose an integrated workflow to manage thyroid nodules using sonographic, cytological 
and molecular data. 
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Sonographic evaluation 
 
Methods 
 
Definition of sonographic features and interobserver reliability 
 
First of all, a literature review was performed to retrieve all the sonographic features 
predictive of malignancy and included in the sonographic classification systems recommendations 
already available at the time (Grant, et al. 2015; Horvath, et al. 2009; Kwak, et al. 2011; Kwak, et 
al. 2013; Mohammadi and Hajizadeh 2013; Ozel, et al. 2012; Park, et al. 2009; Russ, et al. 2013; 
Seo, et al. 2015; Su, et al. 2014). A standardized rating form was designed (Box 1) and an electronic 
database for data collection was developed.  
 
Box 1: Standardized rating form for sonographic features (an electronic version was used for 
consistent data collection). 
 
 Thyroiditis US pattern 
 
Diameters (mm) _______ x ________ x ________ [transverse, anteroposterior, longitudinal] 
 Taller-than-wide (yes/no) 
Margins 
 Sharp 
 Irregular/Microlobulated 
 Ill-defined 
 Infiltrating 
 Hypoechogenic halo 
 
Suspected extrathyroidal extension  
 No 
 Yes 
 
Internal architecture 
 Cystic nodule 
 Solid nodule 
Mixed nodule 
 Spongiform nodule  
 Solid component 
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o Nodular solid component 
 Eccentric  
 Central 
o Non-nodular 
o Septate cyst 
 
Echogenicity 
 isoechogenic  
 hypoechogenic  
 markedly hypoechogenic 
 hyperechogenic 
 anechogenic 
 
Hyperechoic foci 
 “comet-tail-artifact” foci  
 indeterminate foci  
 
Calcifications 
 Microcalcifications (≤ 2 mm, with acoustic shadowing) 
 Macrocalcifications (including eggshell calcifications) 
 
Homogeneity 
 homogeneous 
 inhomogeneous 
 
Vascularity 
 (1) None detectable  
 (2) Peripheral only 
 (3) Central only or central and peripheral 
 
□ Suspicious lymph nodes 
 
The definitions of the various sonographic features were based on the current literature and 
preliminarily shared between the examiners, to ensure consistency (Table 4).  
 
Table 4: definitions of the various sonographic features 
Feature Options Definition 
Composition Solid almost entirely composed of solid tissue 
Mixed both cystic and solid portions are present 
Cystic completely or almost completely anechoic nodule 
Spongiform 
 
Small cysts representing at least 50% of the 
nodule volume 
Echogenicity Marked hypoechogenicity Hypoechoic relative to adjacent strap muscle 
Mild hypoechogenicity Hypoechoic relative to thyroid parenchyma 
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Isoechogenicity Same echogenicity of thyroid parenchyma 
Hyperechogenicity Hyperechoic relative to thyroid parenchyma 
Shape Wider-than-tall Anteroposterior diameter equal or less than the 
transverse one 
Taller-than-wide Anteroposterior diameter greater than the 
transverse one 
Margin Sharp Clearly discernible smooth edge 
Irregular/microlobulated Spiculation, microlobulation, or jagged 
appearance 
Infiltrative Digitative soft tissue protrusions into the 
surrounding tissue 
Ill-defined Poorly demarcated margin which cannot be 
clearly distinguished by the surrounding tissue 
Halo Thin or thick hypoechoic rim surrounding nodule 
(not described if irregular, microlobulated or 
infiltrative) 
Calcification Absent 
 
Microcalcification Echogenic foci of 2 mm or less with or without 
posterior acoustic shadowing within solid portion 
Macrocalcification Echogenic foci of more than 2 mm with posterior 
acoustic shadowing, including eggshell 
calcifications 
Other 
echogenic foci 
Absent 
 
Comet-tail artifact Echogenic foci with reverberation artifacts within 
cystic component 
Indeterminate Small echogenic foci without acoustic shadowing 
nor reverberation; small linear foci, including 
areas of fibrosis 
Extrathyroidal 
extension 
No 
 
Suspicious loss of the echogenic thyroid border, abutment, or 
contour bulging 
 
However, because interobserver variability has been documented during assessments of the 
single sonographic features of thyroid nodules (Grani, et al. 2015), we preliminarily performed an 
internal assessment of variability between the two examiners actually involved. We conducted a 
retrospective analysis of 1055 ultrasound images of thyroid nodules identified in 265 patients (each 
with less than four nodules). All had originally been classified as benign (those with suspicious US 
features but benign cytology) or presumably benign (nodules with no suspicious ultrasound 
features) and managed with active surveillance as long as there was no evidence of malignancy.  
The images had been acquired in our center at the time of nodule detection and/or during the first 
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five years thereafter and stored in order to precisely document the main nodule features over time. 
For the purposes of this analysis, the images of the 1055 nodules (at various follow-up points) were 
converted to and stored as deidentified bitmap files. The blinded files were then randomly divided 
into two groups: set 1 (501 nodules) and set 2 (554 nodules). 
The selected of each nodule in set 1 was independently reviewed on a single liquid crystal display 
monitor by two clinicians, each with 6 years of experience in thyroid US imaging, but trained in 
two different thyroid units. The readers were blinded to the identity of the patient, the date of the 
scan, and all other clinical information regarding the case. Using the standard form (Box 1) the two 
readers rated the various US features of each nodule. For each nodule, the ratings of each reader  
were used to classify the nodule according to the following five systems: American Association of 
Clinical Endocrinologists/American College of Endocrinology/Associazione Medici Endocrinologi 
(AACE/ACE/AME); the TIRADS system developed by the American College of Radiologists 
(ACR); the 2015 ATA Guidelines; the EU-TIRADS system proposed by the European Thyroid 
Association; and the Korean Society of Thyroid Radiology’s K-TIRADS system.  
Two weeks after their independent reviews and classification of set 1 images, the two 
readers jointly reviewed the results and the images of all 501 nodules. Discrepancies between their 
ratings were discussed and a consensus decision reached for each nodule feature.  Four weeks after 
completion of the training session, the two readers were asked to independently review US images 
of the 554 nodules of set 2, repeating the above procedure. 
For each set of nodules, inter-reader agreement was calculated for single features of the 
nodule, risk-class assignment based on each of the five US classification system, and the indication 
of FNAB biopsy based on the risk-class assignments. Agreement on ordinal ratings was assessed 
with the Krippendorff α statistic (Hayes and Krippendorff 2007). Values close to 1 indicate high 
inter-reader agreement, and values above 0.65 are considered an acceptable basis for tentative 
conclusions. Interobserver agreement on nominal, dichotomic ratings was evaluated using Cohen’s 
kappa statistic. Values less than 0.20 are considered indicative of slight agreement; 0.21 to 0.40, fair 
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agreement; 0.41 to 0.60, moderate agreement; 0.61 to 0.80, substantial agreement; and 0.81 to 1.00, 
near-perfect agreement (Landis and Koch 1977). 
Table 5 shows the interobserver agreement for the recognition of single US features in Set 1 
and Set 2. The agreement improved after the set 1 training and discussion session. 
 
Table 5: Interobserver agreement for the recognition of single US features Krippendorff alpha 
(95% confidence intervals) 
 Set #1 Set #2 
Nodules 501 554 
Echogenicity 0.56 
(0.46-0.66) 
0.66 
(0.59-0.73) 
Composition 0.52 
(0.34-0.68) 
0.5 
(0.29-0.68) 
Margin 0.51 
(0.43-0.58) 
0.44 
(0.34-0.53) 
Calcification 0.8 
(0.63-0.93) 
0.89 
(0.75-1) 
Micro- 0.49  
(-0.28-1) 
0.39 
(-0.49-1) 
Macro- 0.85 
(0.59-1) 
0.83 
(0.6-1) 
Echogenic foci 0.48 
(0.3-0.64) 
0.35 
(0.17-0.52) 
Capsule invasion 0.11 
(-0.91-1) 
0.4 
(-1-1) 
 
Table 6 summarizes the data on interobserver agreement nodule risk classification for the 
five reporting systems tested, and the agreement in the identification of nodules that required FNAB 
biopsy. 
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Table 6. Inter-observer agreement for nodule classification and on indications for FNAB 
biopsy according to five sonographic classification systems endorsed by scientific societies. 
 
 
Nodule classificationa Indication to biopsyb 
 Set 1 
(n=501) 
Set 2  
(n=554) 
Set 1 
(n=501) 
Set 2  
(n=554) 
AACE/ACE/AME 0.47 (0.35-0.57) 0.61 (0.49-0.72) 0.73 (0.64-0.82) 0.82 (0.75-0.89) 
ACR TIRADS 0.49 (0.4-0.57) 0.57 (0.5-0.63) 0.61 (0.5-0.72) 0.73 (0.63-0.82) 
ATA 0.49 (0.41-0.57) 0.65 (0.58-0.71) 0.75 (0.67-0.82) 0.82 (0.75-0.89) 
EU-TIRADS 0.61 (0.54-0.68) 0.75 (0.69-0.81) 0.68 (0.58-0.79) 0.74 (0.65-0.83) 
K-TIRADS 0.53 (0.43-0.62) 0.66 (0.57-0.73) 0.82 (0.76-0.88) 0.91 (0.86-0.95) 
 
a) Krippendorff alpha (95% confidence intervals) 
b) Cohen kappa (95% confidence intervals) 
 
On the whole, classification of thyroid nodules using sonographic classification systems produces 
an higher inter-observer agreement than classification based on single suspicious features. More 
importantly, identification of nodules that require FNAB biopsy based on these classification 
systems is associated with substantial to near-perfect agreement. However, there is clearly room for 
further improvement. Given these results (Grani, et al. 2018b), judgments for the prospective cohort 
were made jointly in an effort to improve consistency and reliability.   
 
 
Prospective cohort enrollment 
 
All patients consecutively referred to the unit for FNAB cytology of a thyroid nodule 
between November 1, 2015 and September 10, 2018 were eligible for enrollment. The referring 
23 
 
physicians included primary care physicians and secondary health-care providers (e.g., 
endocrinologists, surgeons, otolaryngologists, nuclear medicine specialists). The study was 
conducted with institutional review board approval and written informed patient consent. A first 
subset of the results has already been published (Grani, et al. 2018a). 
 
Pre-FNAB ultrasound examination of the nodules 
 
Prior to each biopsy, each nodule was carefully examined with a HI VISION Avius® 
ultrasound system (Hitachi Medical Corporation, Inc., Tokyo, Japan) and a 13-MHz linear-array 
transducer. During this examination, two clinicians experienced in thyroid sonography recorded 
their consensus judgement on the sonographic features of each nodule on the previously described 
and internally-developed standardized rating form (Box 1) (Grani, et al. 2017) 
 
Classification of nodules using five sonographic risk-stratification systems 
 
For each nodule, the consensus ratings of each ultrasound feature were used to classify the 
risk of malignancy according to five widely used ultrasound risk-stratification systems (Table 1), 
those published by the AACE/ACE/AME (Gharib et al. 2016); the American College of 
Radiologists (ACR-TIRADS) (Tessler et al. 2017); the ATA (Haugen et al. 2016); the European 
Thyroid Association (EU-TIRADS) (Russ, et al. 2017); and the K-TIRADS (Shin, et al. 2016). 
Since none of these systems routinely recommends the FNAB of sub-centimeter thyroid nodules, 
the nodules with a maximum diameter less than 1 cm were excluded. Using each system, we 
identified the nodules for which FNAB was suggested based on the size threshold for the assigned 
risk class. For this study, nodules that could not be classified according to the ATA Guidelines (e.g. 
isoechoic nodules with other suspicious features like microcalcification, irregular margins, and 
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taller-than-wide shape) were considered intermediate-suspicion nodules, since their risk of 
malignancy is similar (Rosario, et al. 2017; Yoon, et al. 2016). 
 
Reference standard diagnosis 
 
The biopsies were done under ultrasound guidance using 23-25-gauge needles. The non-
aspiration technique was used in most cases (1-4 needle passes). Direct smears of each specimen 
were analyzed by experienced thyroid cytopathologists and classified according to the criteria 
published in the Italian Consensus for Thyroid Cytopathology (Fadda, et al. 2010; Nardi et al. 2014) 
(Table 2). If surgery had been performed, the reference standard diagnosis was based on 
histological examination of the resected nodule. If the nodule had been managed non-surgically, the 
reference standard was FNAB cytology: nodules were considered malignant if they had been 
classified as TIR4 or TIR5 (suspected malignancy or malignancy), and benign if they had been 
classified as TIR2. Nodules without histologic diagnoses that had been cytologically classified as 
non-diagnostic, TIR3A, or TIR3B (indeterminate) were excluded from the final analysis, unless a 
repeat FNAB had yielded conclusive results.  
 
Statistical analysis  
 
For each classification system, we calculated the number of nodules that did (or did not) 
meet the criteria for FNAB (test positivity and test negativity, respectively). The sonographic 
recommendation regarding FNAB was then compared with the reference-standard diagnosis to 
estimate sensitivity, specificity, PPV, NPV, area under the receiver operating characteristics curve 
(AUROC), and diagnostic odds ratios (DOR), each with 95% confidence intervals (CIs). The 
proportions of biopsies that would have spared by the various systems were compared using the 
McNemar test, and the reliability of these indications was assessed by calculation of the NPV and 
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FNR. Data were analyzed with the IBM SPSS Statistics package, version 25.0 (IBM Corp., 
Armonk, NY, US). 
Results 
 
As shown in Figure 1, a total of 917 nodules were sonographically evaluated prior to 
cytology. The examination identified 82 subcentimeter nodules, which were excluded from our 
analysis because FNAB is not routinely indicated by international guidelines for nodules smaller 
than 1 cm. Of the 835 nodules measuring at least 1 cm, 282 were also excluded because their 
reference-standard diagnosis was inconclusive. The final cohort included 553 nodules, of which 42 
(7.6%) were classified as malignant (Tables 7-8), from 524 patients (Table 9). 
 
Figure 1: Flow-chart of the enrollment of the prospective cohort 
 
N=917
Consecutive nodules submitted to FNAB
N=835
Nodules > 1 cm
N=553
Final cohort
Excluded
No final diagnosis
(n=282)
Excluded
Sub-centimeter (n=82)
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Table 7. Sonographic features of the 553 nodules included in the final cohort 
 
  mean±SD 
Diameters (mm) Anteroposterior 13.59±6.58 
Transverse 17.32±8.33 
Longitudinal 22.04±10.09 
Maximum diameter 22.30±10.06 
  N % 
Location (lobe) Right 229 41.4 
Left 281 50.8 
Isthmus 43 7.8 
Single nodule 177 32,0 
Margins Regular 188 34.0 
Ill-defined 67 12.1 
Irregular/lobulated 34 6.1 
Infiltrating 3 0.5 
Halo 261 47.2 
Extrathyroidal extension Suspicion 5 0.9 
Composition Mostly cystic 8 1.4 
solid 185 33.5 
Mixed 371 65.1 
of which, spongiform 13 2.4 
Echogenicity (of the solid 
component, if any) 
Anechoic 3 0.5 
Hyperechoic 2 0.4 
Isoechoic 407 73.6 
Hypoechoic 125 22.6 
Markedly hypoechoic 16 2.9 
Echogenic foci Comet-tail 25 4.5 
Indeterminate 105 19.0 
Calcifications Macrocalcifications 80 14.5 
Microcalcifications 42 7.6 
Shape Taller than wide 94 17.0 
Suspicious lymph nodes Yes 7 1.3 
 
Table 8. Cytological report of the 553 nodules included in the final cohort 
Italian consensus for reporting 
thyroid cytology class 
TIR 1 1 0.2 
TIR 2 495 89.5 
TIR 3A 9 1.6 
TIR 3B 20 3.6 
TIR 4 13 2.4 
TIR 5 15 2.7 
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Table 9. Clinical features of the 524 patients enrolled in the final cohort 
Age years, median (IQR) 56 (46-67)  
  N % 
Gender Male 127 24.2 
Female 397 75.8 
Chronic thyroiditis Clinical 35 6.7 
Sonographic appearance  33 6.3 
Family history of cancer Not reported 458 87.4 
Differentiated thyroid cancer 39 7.4 
Colorectal cancer 2 0.4 
Breast cancer 3 0.6 
Prostate cancer 2 0.4 
Lung cancer 5 1.0 
Others 15 2.9 
Personal history of cancer Not reported 488 93.1 
Colorectal cancer 3 0.6 
Breast cancer 15 2.9 
Prostate cancer 1 0.2 
Lung cancer 2 0.4 
Others 15 2.9 
 
 
Strict application of the five ultrasound systems would have appreciably reduced the number 
of FNAs performed (Table 10). The percentages of avoidable biopsies varied widely (from 16.6% 
to 51.9%). The most effective system in this cohort was the ACR TIRADS, which would have 
spared over half the biopsies performed (287, 51.9%), with a false-negative rate of only 2.8% (NPV 
97.2%; 95% CI 94.6–98.8%). Except for K-TIRADS, the discriminatory capacities of the systems 
(as reflected by their AUROC and DOR; Table 11, Figure 2) were similar to that of the ACR 
TIRADS, but their impact on the number of procedures performed was significantly smaller. 
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Table 10: number of avoidable biopsies and diagnostic performance of the five sonographic classification systems. 
 
Avoidable 
biopsies 
(%) 
TP FP FN TN FNR Sensitivity Specificity PPV NPV 
AACE 189 
(34.18%) 
36 328 6 183 3.17% 85.71% 
(71.46-94.57%) 
35.81% 
(31.65-40.14%) 
9.89% 
(7.02-13.43%) 
96.83% 
(93.22-98.83%) 
ACR 
TIRADS 
287 
(51.90%) 
34 232 8 279 2.79% 80.95% 
(65.88-91.4%) 
54.6% 
(50.17-58.98%) 
12.78% 
(9.02-17.4%) 
97.21% 
(94.58-98.79%) 
ATA 
(modified) 
141 
(25.50%) 
38 374 4 137 2.84% 90.48% 
(77.38-97.34%) 
26.81% 
(23.02-30.88%) 
9.22% 
(6.61-12.44%) 
97.16% 
(92.9-99.22%) 
EU-
TIRADS 
165 
(29.84%) 
36 352 6 159 3.64% 85.71% 
(71.46-94.57%) 
31.12% 
(27.12-35.33%) 
9.28% 
(6.58-12.61%) 
96.36% 
(92.25-98.65%) 
K-
TIRADS 
92 
(16.64%) 
39 422 3 89 3.26% 92.86% 
(80.52-98.5%) 
17.42% 
(14.23-20.99%) 
8.46% 
(6.08-11.38%) 
96.74% 
(90.77-99.32%) 
 
The rate of avoided biopsies is significantly different between the US classification systems (McNemar test; ACR TIRADS vs. ATA, p=0.002, ATA 
vs. AACE/ACE/AME, p<0.001, AACE/ACE/AME vs. EU-TIRADS, p<0.001; EU-TIRADS vs. K-TIRADS, p<0.001). 
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Table 11: Diagnostic odds ratio (DOR) and area under the receiver operating curve (AUROC) 
of the five sonographic classification systems applied to the same cohort. 
 
DOR (95% CI)a AUROC (95% CI)b 
AACE/ACE/AME 3.348 (1.384-8.095) 0.608 (0.55-0.665) 
ACR TIRADS 5.111(2.320-11.257) 0.678 (0.614-0.742) 
ATA 3.480 (1.219-9.932) 0.586 (0.538-0.635) 
EU-TIRADS 2.710 (1.119-6.562) 0.584 (0.527-0.641) 
K-TIRADS 2.742 (0.829-9.070) 0.551 (0.509-0.594) 
a) the DOR measures the discriminatory power of a diagnostic test as compared with that of 
the reference standard. The value ranges from 0 to infinity, with higher values indicating 
better performance; 
b)  the multiple comparisons of AUROC were performed using Bonferroni correction; K-
TIRADS had a significantly lower diagnostic performance than ACR TIRADS (adj. 
p=0.01). 
 
Figure 2: Computed ROC curves (dichotomous test result: biopsy indication) of the five 
systems. 
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The actual malignancy rate was consistent to the predicted risk of malignancy proposed by 
the systems (Table 12), except for the high-risk classes. In these cases, the estimated malignancy 
risk was higher than the measured one. Furthermore, the estimates provided by the K-TIRADS 
classification were higher than the actual risk of malignancy (for all classes). 
 
Table 12: Malignancy rate and estimated malignancy risk of the various risk classes proposed 
by five sonographic classification systems. 
 Malignancy rate Estimated malignancy risk 
AACE/ACE/AME Low 0.0% 1.0% 
Intermediate 3.7% 5-15% 
High 16.8% 50-90% 
ACR TIRADS 1 0.0% 2.0% 
2 2.0% 2.0% 
3 1.9% 3.0% 
4 6.4% 5-20% 
5 28.9% >20% 
ATA Benign 0.0% <1% 
Very low 1.9% <3% 
Low 3.5% 5-10% 
Intermediate 16.1% 10-20% 
High 32.2% >70/80% 
Not classifiable 9.3% - 
EU-TIRADS 2 0.0% 0.0% 
3 2.3% 2-4% 
4 7.7% 6-17% 
5 17.2% 26-87% 
K-TIRADS 2 0.0% <1-3% 
3 2.3% 3-15% 
4 10.6% 15-50% 
5 47.2% >60% 
 
Eight nodules definitively diagnosed as malignant would have been misclassified as not 
requiring FNAB by at least one of the TIRADS systems (Table 13): they were all low risk PTC, 
except for a small medullary thyroid cancer. 
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Table 13: Ultrasound features of the malignancies missed by one or more sonographic 
classification systems 
    Missed by  
 
Size 
(mm) 
ACR TIRADS Modified 
ATA 
K-TIRADS EU-TIRADS 
and AACE 
hyperechoic solid nodule in 
thyroiditis (FV-PTC) 
13 X X X X 
hypoechoic solid nodule (PTC) 13 X  
 
X 
isoechoic mixed nodule (suspected 
PTC) 
11 X X X X 
isoechoic nodule with irregular 
margins (PTC) 
11 X   
 
isoechoic mixed nodule (PTC) 15 X X  X 
isoechoic mixed nodule (FV-PTC) 13 X X X X 
hypoechoic solid nodule (MTC) 12 X   X 
Micro-PTC in the context of a 39-
mm follicular adenoma (isoechoic 
mixed nodule) 
- X 
 
 
 
 
 8 4 3 6 
Abbreviations: ACR TIRADS: American College of Radiology Thyroid Imaging Reporting and  
Data Systems; ATA: American Thyroid Association; EU-TIRADS: European Thyroid Imaging 
Reporting and Data Systems; MTC: medullary thyroid cancer; PTC: papillary thyroid cancer; K-
TIRADS: Korean Thyroid Imaging Reporting and Data Systems 
 
Discussion 
 
Thyroid cytology used to be the cornerstone of the diagnostic workflow of thyroid nodules. 
In roughly one third of cases, cytomorphologic analysis of the aspirate yields inconclusive results 
(Bongiovanni et al. 2012) that prompt repeat biopsies or additional, more expensive testing 
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(Lamartina, et al. 2016). The sonographic risk-stratification tools are designed as “rule-out” tests, 
aiming to identify nodules with low risks of malignancy whose cytologic assessment can safely be 
deferred. The first aim of this project was to prospectively validate current sonographic 
classification systems for the risk evaluation of thyroid nodules. Four of the five sonographic 
stratification systems confirmed a statistically significant discriminatory capacity (all except K-
TIRADS): the number of biopsies performed would have been reduced applying the internationally-
endorsed classification systems. However, the safest and most substantial reduction would have 
been achieved with the ACR TIRADS: the number of deferred biopsies and its ability to 
discriminate between benign and malignant nodules were greater than those of the competitors.  
The study has some limitations. First, this was a selected cohort of thyroid nodules, all of 
which had already been flagged for FNAB, and the clinical criteria supporting these indications 
were not known. The malignancy rate, however, was similar to those reported for unselected nodule 
series (Durante et al. 2018), and all sonographic risk classes were represented, including low-risk 
categories. Second, we used a composite reference standard: a benign cytology report was 
considered sufficient for classification. However, cytology can yield false-negative results, even if 
uncommonly, with estimated frequencies of 3.7% (Bongiovanni et al. 2012) and even lower (<1%) 
in prospective series of cytologically benign nodules with no high-suspicion ultrasound features 
(Durante, et al. 2015). Furthermore, the exclusion of nodules with non-diagnostic or indeterminate 
cytology reports (and no final histology) may have caused a selection bias: however, the proportion 
of nodules with these cytological reports is consistent with those reported in other cytological series 
(Bongiovanni et al. 2012). The major strength of our study is its prospective nature: the US features 
of each nodule were evaluated during real-time examinations carried out before aspirates were 
collected. Our results support the use of sonographic classification systems to reduce the number of 
needed thyroid nodule biopsies. The best overall performance was that of the ACR TIRADS, which 
classified over half of the requested biopsies as unnecessary. 
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Molecular evaluation 
 
A new molecular platform for the refinement of cytologic diagnoses was designed and tested 
on a retrospective surgical cohort of resected thyroid nodules, for which a cytological examination 
was previously performed, and the relative material was available for molecular testing. 
 
Methods 
 
Sample collection 
 
A retrospective series of FNAB samples with cytological diagnosis performed from June 
2016 to December 2017 and subsequently submitted to thyroid surgery were enrolled. For this 
reason, the indeterminate, suspicious or malignant reports were more prevalent (Figure 3).  
At the time of ultrasound-guided FNAB procedure, a liquid-based cytology sample was prepared, to 
be processed with ThinPrep5000™ system (Hologic Co.). The material remaining after cytological 
analysis was used for molecular profiling. 
Nucleic acids were isolated from each sample using the AllPrep DNA/RNA Micro Kit 
(QIAGEN) which allows the simultaneous purification of genomic DNA and total RNA from the 
same biological sample. Samples will be accurately measured using the highly sensitive 
fluorescence-based Qubit® dsDNA/RNA High Sensitivity quantification assays (Thermo Fisher 
Scientific).  
 
Molecular Analysis through targeted Next-Generation Sequencing 
 
Genetic analysis was performed on the Ion S5 system (Thermo Fisher Scientific) using two 
custom NGS multi-gene panels, which tested for single-nucleotide variants/small indels/copy 
number amplification (DNA panel) and gene fusions/gene expression (RNA panel) involving well-
known thyroid cancer-related genes (e.g., BRAF, RAS, EIF1AX, TERT, RET/PTC, and PAX8/ 
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PPARG fusion) and others from our in-house database. Genes for the custom panel were selected 
based on literature data (Cancer Genome Atlas Research  Network 2014; Landa et al. 2016; 
Nikiforov, et al. 2014) and our in-house database, and custom primers for their targeted 
amplification were designed with the Ion AmpliSeq™ Designer (Thermo Fisher Scientific). Two 
libraries were created from 20 ng of DNA and 20 ng of RNA. The targeted amplification products 
were partially digested, phosphorylated, and ligated to Ion P1 adapter and Ion Xpress™ barcodes 
(Thermo Fisher Scientific). Libraries were pooled and clonally amplified on the Ion One Touch2 
System. Sequencing was performed using Ion S5 sequencing solution on an Ion 530 chip (Thermo 
Fisher Scientific).  
Data analysis 
 
Data were analyzed with Variant Caller v5.4, annotated with Ion Reporter 5.6 and 
wANNOVAR software and prioritized on the basis of their population frequency (Minor allele 
frequency <0.005).  Predicted variant deleteriousness was assessed with wANNOVAR 
(http://wannovar.wglab.org/). 
SNVs and Indels were called when the position was covered by over 500 reads. The lower 
detection limits were set at 5% for SNVs and 15% for small indels. CNA will be called when 
variant will have a confidence level more than 15. The presence of at least 50 high-quality reads 
crossing the fusion point of the transcript will be required to consider the test positive.  
 
Digital PCR quantification of microRNA 
 
Dysregulated miRNA expression has been documented and characterized at the tissue level 
in many malignancies, including thyroid cancer. We decided to evaluate the expression of a single 
miR (miR-146b-5p). It was selected because it is specifically expressed in follicular-cell-derived 
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malignant thyroid neoplasms, based on results previously published by our group (Rosignolo, et al. 
2017a; Rosignolo, et al. 2017b). 
Expression analysis of miR-146b-5p was performed by digital PCR, using a QuantStudio 3D 
Digital PCR equipment (Thermo Fisher Scientific), using 1.25 ng of RNA, with standard 
procedures.  Expression suite software v 1.0.3 (Thermo Fisher Scientific) was used to determine 
relative miRNA expression, using U6 as an endogenous control. The optimal cutoff level was 
selected using receiver-operating characteristic (ROC) curve analysis (p-ROC package in R 
software, version 3.1.1, Figure 3).  
 
Figure 3: ROC curve analysis of mIR-146b-5p quantification, performed to select the optimal 
cut-off point (0.1503). 
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Figure 4: Diagnostic performance of mIR-146b-5p/U6 ratio using the cut-off point derived by 
the ROC curve analysis (specificity 96%, sensitivity 71%). 
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Reference standard 
 
Surgical histology was used as the reference standard. Noninvasive follicular thyroid 
neoplasm with papillary-like nuclear features (NIFTP), a recently defined entity (Nikiforov, et al. 
2016), previously considered an encapsulated noninvasive follicular-variant papillary thyroid 
cancer, is to date variably considered as nonmalignant, premalignant, or possibly carcinoma in situ. 
For the purposes of this study, it was considered a lesion with extremely low malignant potential, 
according to the statement of the ATA expert panel (Haugen, et al. 2017). Furthermore, it cannot be 
grouped with benign nodules, as it requires surgical management (Nikiforov 2017). 
 
Statistical analysis  
 
The NGS test was considered positive if a known driver mutation was found (with any allele 
frequency) or an unknown mutation in driver genes was found with an allele frequency >10%. The 
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digital PCR test was considered positive if the ratio miR-146b-5p/U6 was > 0.1503 (Figure 4). The 
combined test was considered positive if one of the two components (NGS or miR-146b-5p) was 
positive, and negative if both components were negatives. 
The test result was then compared with the reference-standard diagnosis to estimate its 
sensitivity, specificity, positive and negative predictive values (PPV and NPV) and areas under the 
receiver operating characteristic (AUROC) curve (each with 95% confidence intervals, [CIs]). Data 
were analyzed with the IBM SPSS Statistics package, version 25.0 (IBM Corp., Armonk, NY, US). 
 
Results 
 
From the original cohort of 157 samples with histology, from 140 patients, 38 inadequate 
samples (23%) were excluded: the molecular analysis was then performed in 119 samples from 113 
patients (Figure 5; Table 14). Among them, 54 were histologically classified as benign (31 nodular 
hyperplasia/goiter; 23 adenomas), and 65 as malignant (61 papillary thyroid cancers – including 2 
NIFTP, 1 follicular thyroid cancer, 1 poorly differentiated thyroid cancer, 1 anaplastic thyroid 
cancer, and 1 medullary thyroid cancer). 
 
Figure 5: Flow-chart of the enrollment of the retrospective cohort 
 
157 samples with histology 
(140 Patients) 
119 samples with molecular test 
(113 Patients) 
38 samples (23%) excluded 
33 Low RNA and/or DNA 
4 only NGS analysis 
1 Failed Library 
40 samples with indeterminate 
cytology 
(39 Patients) 
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Table 14. Demographic features of the patients (whole cohort and indeterminate cytology 
cohort) 
 All 119 samples  40 indeterminate 
samples 
Age 48.7 (18-91) 52.9 (32-79) 
Male 28 (25%) 11 (28%) 
Female 85 (75%) 28 (72%) 
N 113 patients 39 patients 
 
The NGS panel identified 69 nodules harboring somatic alterations involving a known 
driver gene, the most common being BRAF, followed by RAS (N-, H-, and K-RAS grouped 
together) (Table 15).  
 
Table 15. Driver mutations identified by the NGS panel 
  N % 
None 50 42.0 
BRAF 43 36.1 
NRAS 6 5.0 
EIF1AX 4 3.4 
HRAS 4 3.4 
RET/PTC1 4 3.4 
KRAS 2 1.6 
RET 2 1.7 
CHEK2 1 0.8 
PAX8-PPARG 1 0.8 
PTEN233 1 0.8 
RET/PTC3 1 0.8 
 
The resulting diagnostic performance is reported in Table 16. The overall sensitivity is 
87.69% (95% CI 77.18-94.53%), specificity of 77.78% (64.4-87.96%), PPV 82.61% (71.59-
39 
 
90.68%) and NPV of 84% (70.89-92.83%). Considering only cytologically indeterminate nodules, 
the sensitivity is 88.89% (51.75-99.72%), specificity 80.65% (62.53-92.55%), PPV 57.14% (28.86-
82.34%), and NPV 96.15% (80.36-99.9%).  Thus, 12 false positive cases were found:  5 (41.7%) 
involving RAS genes, 3 (25%) EIF1AX, and BRAF, CHEK2, PTEN, and RET genes (1 case each; all 
of them were carefully checked by the pathologists, and the absence of histology features of 
malignancy was confirmed).
40 
 
 
Table 16: Diagnostic performance of the Next Generation Sequencing panel (overall and according to cytology classes; indeterminate 
cytology categories are highlighted in gray) 
 
 
 TP FP FN TN n Sensitivity Specificity PPV NPV 
NGS, overall  57 12 8 42 119 87.69% 
(77.18-94.53%) 
77.78% 
(64.4-87.96%) 
82.61% 
(71.59-90.68%) 
84.0% 
(70.89-92.83%) 
According to cytology classes 
TIR 2 
 
0 4 1 16 21 0.0% 
(0.0-97.5%) 
80.0% 
(56.34-94.27%) 
0.0%  
(0.0-60.24%) 
94.12% 
(71.31-99.85%) 
TIR 3A 
 
1 1 0 7 9 100.0% 
(2.5-100.0%) 
87.5% 
(47.35-99.68%) 
50.0% 
(1.26-98.74%) 
100.0% 
(59.04-100.0%) 
TIR 3B 
 
7 5 1 18 31 87.5% 
(47.35-99.68%) 
78.26% 
(56.3-92.54%) 
58.33% 
(27.67-84.83%) 
94.74% 
(73.97-99.87%) 
TIR 3A and B   8 6 1 25 40 88.89% 
(51.75-99.72%) 
80.65% 
(62.53-92.55%) 
57.14% 
(28.86-82.34%) 
96.15% 
(80.36-99.9%) 
TIR 4 
 
19 2 3 0 24 86.36% 
(65.09-97.09%) 
0.0% 
(0.0-84.19%) 
90.48% 
(69.62-98.83%) 
0.0% 
(0.0-70.76%) 
TIR 5 
 
30 0 2 0 32 93.75% 
(79.19-99.23%) 
- 100.0% 
(88.43-100.0%) 
0.0% 
(0.0-84.19%) 
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The miR-146b-5p levels were considered positive in 48 cases. The diagnostic performance 
is reported in Table 17. Since the cutoff level was selected in this same cohort, according to the 
ROC curve analysis, overestimation of diagnostic values is possible, and the determination in an 
independent cohort is needed. In the whole cohort, sensitivity was 70.77% (95% CI 58.17-81.4%), 
specificity 96.3% (87.25-99.55%), PPV 95.83% (85.75-99.49%), and NPV 73.24% (61.41-
83.06%). In the subset of indeterminate nodules, sensitivity was 77.78% (39.99-97.19%), 
specificity 93.55% (78.58-99.21%), PPV 77.78% (39.99-97.19%), and NPV 93.55% (78.58-
99.21%).  
 
The combination of the two tests resulted in a sensitivity of 90.77% (80.98-96.54%), 
specificity 74.07% (60.35-85.04%), PPV 80.82% (69.92-89.1%), and NPV 86.96% (73.74-95.06%) 
in the entire cohort, and a sensitivity of  100.0% (66.37-100.0%), specificity 74.19% (55.39-
88.14%), PPV 52.94% (27.81-77.02%), and NPV 100.0% (85.18-100.0%) in the cytologically 
indeterminate nodule subset (Table 18).  Combining the two tests did not improve the diagnostic 
performance (assessed according to the AUROC analysis) in the entire cohort:  the AUROC for 
mIR, NGS, and combined test were 0.84 (0.77-0.9), 0.83 (0.76-0.9), and 0.82 (0.76-0.89) 
respectively. In the subgroup of indeterminate nodules, the AUROC slightly increases, without 
statistical significance: 0.86 (0.71-1), 0.85 (0.72-0.98), 0.87 (0.79-0.95) for mIR, NGS, and 
combined test, respectively (Figure 6). However, the combination of the two tests zeroed the false 
negative number, allowing for a NPV of 100%.  A greater sample is probably needed to clarify the 
better workflow and combination strategy.
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Table 17: Diagnostic performance of the mIR (overall and according to cytology classes; indeterminate cytology categories are highlighted 
in gray) 
 
 
 TP FP FN TN n Sensitivity Specificity PPV NPV 
miR  46 2 19 52 119 70.77% 
(58.17-81.4%) 
96.3% 
(87.25-99.55%) 
95.83% 
(85.75-99.49%) 
73.24% 
(61.41-83.06%) 
According to cytology classes 
TIR 2 
 
0 0 1 20 21 0.0% 
(0.0-97.5%) 
100.0% 
(83.16-100.0%) 
- 95.24% 
(76.18-99.88%) 
TIR 3A 
 
1 0 0 8 9 100.0% 
(2.5-100.0%) 
100.0% 
(63.06-100.0%) 
100.0% 
(2.5-100.0%) 
100.0% 
(63.06-100.0%) 
TIR 3B 
 
6 2 2 21 31 75.0% 
(34.91-96.81%) 
91.3% 
(71.96-98.93%) 
75.0% 
(34.91-96.81%) 
91.3% 
(71.96-98.93%) 
TIR 3A and B   7 2 2 29 40 77.78% 
(39.99-97.19%) 
93.55% 
(78.58-99.21%) 
77.78% 
(39.99-97.19%) 
93.55% 
(78.58-99.21%) 
TIR 4 
 
15 0 7 2 24 68.18% 
(45.13-86.14%) 
100.0% 
(15.81-100.0%) 
100.0% 
(78.2-100.0%) 
22.22% 
(2.81-60.01%) 
TIR 5 
 
24 0 8 0 32 75.0% 
(56.6-88.54%) 
- 100.0% 
(85.75-100.0%) 
0.0% 
(0.0-36.94%) 
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Table 18: Diagnostic performance of the combination of mIR and Next Generation Sequencing panel (overall and according to cytology 
classes; indeterminate cytology categories are highlighted in gray) 
 
 
 TP FP FN TN n Sensitivity Specificity PPV NPV 
Combination  59 14 6 40 119 90.77% 
(80.98-96.54%) 
74.07% (60.35-
85.04%) 
80.82% (69.92-
89.1%) 
86.96% (73.74-
95.06%) 
According to cytology classes 
TIR 2 
 
0 4 1 16 21 0.0% 
(0.0-97.5%) 
80.0% 
(56.34-94.27%) 
0.0% 
(0.0-60.24%) 
94.12% 
(71.31-99.85%) 
TIR 3A  1 1 0 7 9 100.0% 
(2.5-100.0%) 
87.5% 
(47.35-99.68%) 
50.0% 
(1.26-98.74%) 
100.0% 
(59.04-100.0%) 
TIR 3B  8 7 0 16 31 100.0% 
(63.06-100.0%) 
69.57% 
(47.08-86.79%) 
53.33% 
(26.59-78.73%) 
100.0% 
(79.41-100.0%) 
TIR 3A and B   9 8 0 23 40 100.0% 
(66.37-100.0%) 
74.19% 
(55.39-88.14%) 
52.94% 
(27.81-77.02%) 
100.0% 
(85.18-100.0%) 
TIR 4 
 
19 2 3 0 24 86.36% 
(65.09-97.09%) 
0.0% 
(0.0-84.19%) 
90.48% 
(69.62-98.83%) 
0.0% 
(0.0-70.76%) 
TIR 5 
 
31 0 1 0 32 96.88% 
(83.78-99.92%) 
- 100.0% 
(88.78-100.0%) 
0.0% 
(0.0-97.5%) 
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Figure 6: Computed ROC curves of the NGS, miR, and combined test in the subgroup of 
indeterminate nodules (TIR3A and TIR3B cytology reports) 
 
 
Discussion 
 
We have developed a combination test with a sensitivity of 100.0% (66.37-100.0%) and 
specificity of 74.19% (55.39-88.14%) in the cytologically indeterminate nodule subset. With the 
current prevalence of malignancy (22.5%), it has a PPV of 52.94% (27.81-77.02%) and NPV 
100.0% (85.18-100.0%). It is so possible to use it as a “rule out” test in cytologically indeterminate 
lesions. Furthermore, we have demonstrated that it is possible to have a sufficient amount of nucleic 
acid from the original cytology sample in at least 77% of the cases; with liquid-based cytology 
processing, it also does not require the destruction of the original slide used for morphological 
diagnosis. Finally, the potential availability of mutational data in a pre-surgical setting may help the 
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personalized surgical planning, providing some risk estimation information before the 
thyroidectomy, and may help clinicians to refine the treatment of patients. For example, the 
detection of additional mutations (late genetic events) such as TERT may identify thyroid cancers 
with the highest risk for tumor recurrence and disease specific mortality (Moon, et al. 2017; Song, 
et al. 2016; Vuong, et al. 2017). 
 
While in this cohort of cytologically indeterminate nodules no false negative were detected, 
in the whole cohort 6 false negative were detected: all but two of them were correctly identified by 
cytological examinations. In the 2 cases that resulted false negative both for cytology and for 
molecular testing, a sampling error may not be excluded (the first case had a non-diagnostic 
cytology; in the second case a small, 3-mm PTC was probably not the target of the biopsy). On the 
contrary, some false positives were detected: the majority of them (6/8 in the indeterminate cohort) 
were due to the detection of driver mutation. In these cases, at least an adenoma was identified: it is 
a clonal neoplasm, therefore potentially prone to progression (Figure 7). 
 
Figure 7: Hyperplasia and adenoma and detection of mutations (from Nikiforov, 2017) 
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This study has several limitations. First of all, it is based on a surgical cohort: it is prone to 
selection bias. Furthermore, this study was performed at a single high-volume pathology center with 
established clinical expertise: the results may vary in other settings. Finally, the threshold for 
positivity of miR-146b-5p was established according to the ROC curve analysis in this same cohort, 
thus leading to overestimation of the diagnostic accuracy. An independent validation cohort is 
needed.  
The study reports a high sensitivity and high NPV of our combined test for indeterminate 
cytology nodules, which together with good specificity may avoid surgeries in a good number of 
patients (in our cohort 23 patients may have avoided surgery, 57.5%). 
 
Conclusions 
 
More than 600’000 thyroid FNABs are performed every year in the United States alone, and 
the number has been increasing annually by 16% from 2006 to 2011. In the same time frame, The 
number of thyroid surgeries performed increased by 31%, and total thyroidectomies increased by 
12% per year (Sosa, et al. 2013). About 20% of FNAB of thyroid nodules have indeterminate 
cytology (Bethesda category III and IV) (Durante et al. 2018). The number of diagnostic surgeries 
can be reduced if the nodules are reliably classified as benign. Over the past decade, molecular 
testing of thyroid nodules was developed to improve diagnostic accuracy of FNA cytology: 
development of new test strategies is ongoing, using gene expression profiling, miRNA profiling, 
broader gene panels of for mutational markers, inclusion of copy number alterations, mitochondrial 
DNA, and combinations of different markers. However, the role and optimal application of 
molecular testing is yet to be determined, also considering his high cost. 
The final aim of this project was to propose an integrated workflow to manage thyroid 
nodules using sonographic, cytological and molecular data. 
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The first step is to better select the nodules that really need further examinations. We have 
documented that the application of the ACR TIRADS systems may reduce more than a half of the 
cytological examinations performed at our center, still detecting clinically significant cancers. 
Figure 8: First step of management of newly detected thyroid nodules 
 
Only nodules classified as ACR TIRADS TR3, TR4, TR5 above the defined size cutoff should be 
submitted to FNAB (no more than 50% of the nodules greater than 1 cm). It is important to note, 
however, that the US features being evaluated must also be clearly and unambiguously defined, and 
the application of TIRADS systems requires specific training and experience (Grani et al. 2018b), 
appropriate equipment and sufficient time.  
About 20% of biopsied nodules are expected to have an indeterminate cytology report. In this 
group, the application of the molecular test may be considered: however, its performance is heavily 
dependent on pre-test probability of malignancy. Given the sensitivity and specificity of the 
molecular test, Bayes theorem can predict the test NPV and PPV along the spectrum of disease 
prevalence (i.e. the pre-test probability of disease) (Christenson 2007). The plot of the predicted 
NPV and PPV of our molecular testing approach is reported in Figure 9: the NPV is at least 95% till 
Thyroid nodule
US classification 
using ACR TIRADS
TR 1 - TR2
TR3, TR4, TR5 
below the size 
cutoff
TR3, TR4, TR5 
above the size 
cutoff
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to a 30% pre-test probability of disease. From a clinical point of view, it means that a negative test 
equals the diagnostic performance of a benign cytology report, is a good “rule out” test, and the 
patient may avoid surgery. In most center, the malignancy risk of Bethesda class 5 (or Italian TIR4) 
cytology report is > 30%, so that the clinical performance of diagnostic test is not enough to spare 
surgery.  
Figure 9: Plot of positive and negative predictive values of the developed combined molecular 
testing according to the pre-test probability of disease. The NPV is ≥ 95% for a pre-test 
probability up to 30%. 
  
Furthermore, if at a given center, the malignancy rate of Bethesda class 4 (or TIR3B) lesions is 
>30%, the negative predictive value would be lower than predicted. On the contrary, nodules with 
non-diagnostic or benign cytology with suspicious sonographic features may have a malignancy 
risk around 20% (thus similar to the cytologically indeterminate nodules): in these cases, repeat 
cytology with molecular testing may also be considered. For low-risk indeterminate nodules with no 
49 
 
sonographic suspicion, the predicted malignancy risk may be so low to not justify the cost of 
molecular testing: it would be possible to directly suggest periodic surveillance. 
If the cause of indeterminate cytology is an adenoma, molecular test is also likely to produce false 
positive results, since the RAS and RAS-like gene mutations are associated with neoplasia (and 
frequently reported in adenomas), even if not necessarily with malignancy. Morphologic sub-
grouping of indeterminate cytology reports may also help in guiding the choice of molecular 
testing. In high-risk nodules, the molecular test is not to be used not as a “rule-out” test: however, it 
can detect or exclude mutations associated with aggressive features, thus guiding the extent of 
surgery. 
 
Figure 10: Management of thyroid nodules submitted to FNAB cytology 
 
FNAB cytology
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(≈20% 
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cytology ± molecular testing 
If overall low risk: active 
surveillance may be preferred  
Molecular testing 
Molecular test as a rule-out test (up to 30% malignancy 
risk); for higher risk, consider to guide surgery 
Molecular test to guide treatment choices (active 
surveillance, lobectomy, total thyroidectomy, lymph 
node dissection) 
Long-term follow-up 
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In conclusion, the traditional approach to the thyroid nodule, based on cytology, is changed. 
Nowadays, the leading examination is the neck sonography, that may be used to spare about the half 
of previously suggested biopsies. Among the sampled nodules, the cytologically indeterminate 
lesions may be managed in a more conservative way, sparing a relevant number of diagnostic 
surgeries, with an appropriate use of molecular tests. In our cohort, half of the surgeries performed 
for indeterminate nodules could be avoided. Furthermore, the risk estimation provided by both the 
cytology and the sonographic examination may contribute to the pre-molecular test probability of 
malignancy, optimizing the diagnostic performance and potentially contributing to the cost-
effectiveness, that is yet to be determined in a European public health system such as the Italian 
one. 
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